Smith & Nephew (LSE:SN.) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:SN. Smith & Nephew PLC LSE:SN.
83 GF Score
Price £11.51
GF Value £11.93
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Smith & Nephew FFO per Share?

FFO per Share only applies to REITs.

LSE:SN.
83GF Score
Smith & Nephew PLC LSE:SN.
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Smith & Nephew (LSE:SN.) Overvalued in 2026?

Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued. The current stock price of £11.51 is trading 3.5% below its estimated GF Value™ of £11.93. GuruFocus considers Smith & Nephew to be Fairly Valued.

Key valuation signals for LSE:SN.:

  • FFO per Share:
  • GF Value™: £11.93 vs. price of £11.51 (3.5% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the LSE:SN. stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Smith & Nephew Business Description

Address Hatters Lane, Building 5, Croxley Park, Watford, Hertfordshire, GBR, WD18 8YE
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
83GF Score

Get the complete analysis for LSE:SN.

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£11.51
Price
£11.93
GF Value